Therefore, both in vitro and in vivo studies suggest that QCT is a promising candidate for treating DN due to its ability to target the Nrf2/HO-1 signaling pathway and dose-dependently inhibit ferroptosis in renal tubular epithelial cells during DN (225). Here, NFE2L2 is linked to liver dysplastic nodule.